42 search results for: allergy
Anju Peters, MD, MS
Professor, Department of Medicine Director of Clinical Research, Division of Allergy-Immunology, Medical Director, Northwestern Medicine Clinical Research Unit Northwestern University Feinberg School of Medicine
Marcus Maurer, MD
Professor of Dermatology and Allergy; Head of Dermatological Allergology; Director of Research at the Department of Dermatology and Allergy and the Allergie-Centrum-Charité, Charité – Universitätsmedizin, Berlin, Germany
Miguel Lanz, MD, FAAAAI
Lanz Allergy, Asthma & Immunology AAADRS Clinical Research Center | Coral Gables, FL
Andreas Wollenberg, MD, PhD
Professor in the Department of Dermatology and Allergy, Ludwig-Maximilian University of Munich, Germany
William Busse, MD
Retired Faculty Member in the Division of Allergy, Pulmonary, and Critical Care Medicine | University of Wisconsin, United States
Stephanie Christenson, MD, MAS
Associate Professor at the University of California, San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine
Martin Metz, MD
Professor in the Department of Dermatology and Allergy, Head of Translational Research, and Deputy Head of Clinical Trials | Charité – Universitätsmedizin, Berlin, Germany
Martin Wagenmann, MD, PhD
Head of Rhinology, Allergy, and Endoscopic Skull Base Surgery and Head of the Research Laboratory in the ENT Department | University Hospital of Düsseldorf, Germany
Thomas Bieber, MD, PhD, MDRA
Prof. Thomas Bieber is Professor of Dermatology and Allergy. He received his degrees in medicine (MD) and biology (PhD in immunology) from the University of Louis Pasteur in Strasbourg, France. He then earned a master’s degree in drug regulatory affairs (MDRA from the University of Bonn), achieving special expertise in preclinical and clinical drug development strategies, as well as in legal and market access aspects of drug development. He has special expertise in translational and precision medicine approaches for skin diseases.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
Angela Bretton, APRN, FNP-BC, MSN
San Diego Allergy and Immunology | Vista, CA
Marta Ferrer, MD, PhD
Head of the Department of Allergy at Navarra University Hospital, Pamplona, Spain
